Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB

Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB

SYDNEY, March 2, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focused specialty pharmaceutical company, for Cantrixil...

Read more: Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia...

More Articles …

  1. Nintex Workflow Cloud Helps Zoom Improve Channel Order Process
  2. K7 Computing Launches Lifetime Valid Antivirus - K7 Ultimate Security Infiniti Edition
  3. CORE to open an Australian office to assist Australian entrepreneurs looking to start a business in Hong Kong
  4. TVM Capital Healthcare Exits Cambridge Medical and Rehabilitation Center for US$ 232 Million, a 4.6x Return on Capital Invested
  5. Atradius Collections expands its global presence with the acquisition of Gestifatura
  6. New private equity investor to drive Hawksford growth strategy
  7. MiX Telematics launches new, Australian Taxation Office-approved solution to simplify Fringe Benefits Tax claims
  8. Acclime establishes a strong foothold in Australia with the acquisition of CoSec Corporate Services
  9. Dating app for couples and singles celebrates Threeway Day on 3/3
  10. Alterity to present at the 7th International Congress of Multiple System Atrophy